Univar Solutions Selected as Ingredion Pharma Solutions Distributor in United States and Canada

Univar Solutions announced that its Ingredients + Specialties division was appointed distributor for Ingredion Pharma Solutions (NYSE: INGR) in the United States and Canada, becoming the exclusive distributor for Ingredion's pharmaceutical starches.

Rhea-AI Summary

Univar Solutions announced that its Ingredients + Specialties division was appointed distributor for Ingredion Pharma Solutions (NYSE: INGR) in the United States and Canada, becoming the exclusive distributor for Ingredion's pharmaceutical starches. The agreement covers a broad pharma portfolio, including UNI-PURE branded starch excipients, mannitol and specialty excipients.

The partnership aims to expand access to functional excipients for tableting, softgels and encapsulation while leveraging Univar's distribution network and technical formulation support.

Argus Feb 24 session

+1.60% close to close Open Argus

Details

News Market Reaction – INGR

In the Feb 24 session, INGR gained 1.60%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights a strategic expansion of Ingredion’s pharmaceutical footprint through a...

Analysis

This announcement highlights a strategic expansion of Ingredion’s pharmaceutical footprint through an exclusive U.S. and Canada distribution partnership for starch-based excipients and related ingredients. It complements prior record 2025 financial results and ongoing corporate recognition for operational excellence. Investors may watch how this agreement contributes to Ingredion’s specialty ingredients mix over time, alongside the company’s existing financing flexibility under its effective S-3ASR debt shelf and recent insider trading activity disclosed in Form 4 filings.

Key Figures

Announcement date: Feb. 24, 2026

Announcement date

Feb. 24, 2026

Distribution partnership press release date

Historical Context

5 past events · Latest: Feb 11

5 events

1. Feb 11

   Leadership change

   24h Move

   +1.0%

   CEO James P. Zallie also elected chairman, reinforcing governance continuity.

2. Feb 03

   Earnings results

   24h Move

   +2.6%

   Record 2025 results with higher EPS, operating income and strong cash generation.

3. Jan 22

   Employer awards

   24h Move

   +0.4%

   Certified Top Employer in eight countries and Asia Pacific region.

4. Jan 21

   Reputation ranking

   24h Move

   +0.4%

   Named to FORTUNE World’s Most Admired Companies list for 16th time.

5. Jan 13

   Earnings date set

   24h Move

   +2.6%

   Announced date and details for Q4 and full-year 2025 results release.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

excipients, direct compression, wet granulation, superdisintegrants, +1 more

5 terms

excipients medical

"Ingredion's functional excipientsDOWNERS GROVE, Ill., Feb. 24, 2026 --"

Excipients are the inactive ingredients in a drug or vaccine that support the active medication—things like fillers, stabilizers, preservatives or substances that help the medicine dissolve or stay fresh. Investors care because excipient choice affects manufacturing cost, shelf life, regulatory approval, supply-chain complexity and patient acceptance; like the packaging and recipe for a product, they can influence profitability, production speed and marketability.

direct compression medical

"functional excipients, including direct compression and wet granulation binders,"

Direct compression is a pill-making method where powdered ingredients are pressed straight into tablets without extra mixing, wetting, or drying steps used in other processes. For investors, it matters because the simpler process cuts manufacturing time, reduces equipment and energy costs, and can speed capacity expansion, but it also requires consistent raw-material quality and can affect yield and regulatory scrutiny—like baking cookies by pressing dough directly instead of preparing and shaping several separate components.

wet granulation medical

"functional excipients, including direct compression and wet granulation binders,"

Wet granulation is a common drug-manufacturing step where powdered ingredients are mixed with a liquid to form moist clumps that are then dried and turned into uniform pellets or tablets—think making snowballs from loose powder so they hold together. It matters to investors because the method affects final product quality, manufacturing speed, yield, and regulatory compliance, all of which influence production costs, supply reliability and the commercial success of a pharmaceutical product.

superdisintegrants medical

"fillers for tablets and capsules, superdisintegrants, lubricants, emulsion for encapsulation,"

Superdisintegrants are specially formulated inert ingredients added to tablets and oral powders to make them break apart quickly when they contact liquid, much like a compressed sponge or sugar cube that falls apart in water. For investors, they matter because they affect how fast a drug is absorbed, patient experience, manufacturing speed and yield, and regulatory acceptance — all of which can influence a product’s marketability, costs and competitive edge.

encapsulation medical

"lubricants, emulsion for encapsulation, and gelatin replacements for vegetarian"

Encapsulation is the process of enclosing an active drug or ingredient inside a tiny carrier—like a microscopic bubble, bead or shell—to protect it, control when and where it’s released, or steer it to particular tissues. For investors, encapsulation can raise a product’s effectiveness, safety profile, shelf life and patent value while also changing development costs, manufacturing complexity and regulatory risk, much like redesigning a delivery system for a consumer product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Pharmaceutical manufacturers will benefit from deep expertise and an extensive distribution network paired with Ingredion's functional excipients

DOWNERS GROVE, Ill., Feb. 24, 2026 /PRNewswire/ -- Univar Solutions LLC ("Univar Solutions" or "the Company"), a leading global solutions provider to users of specialty ingredients and chemicals, today announced that its Ingredients +  Specialties from Univar Solutions division has been appointed as a distributor for Ingredion Pharma Solutions, part of Ingredion Incorporated (NYSE: INGR). The agreement includes distribution of Ingredion's global pharmaceuticals portfolio and positions the Company as the exclusive distributor of pharmaceutical starches in the United States and Canada. This strategic partnership enables Ingredients + Specialties to further diversify and strengthen its pharmaceutical and nutraceutical ingredients portfolios with a broad range of functional excipients, including direct compression and wet granulation binders, fillers for tablets and capsules, superdisintegrants, lubricants, emulsion for encapsulation, and gelatin replacements for vegetarian softgel formulations.

We are thrilled to enhance our product range while deepening our partnership with Ingredion.

"We are thrilled to enhance our product range while deepening our partnership with Ingredion," said Aaron Lee, global senior vice president of Health & Nutrition for Univar Solutions. "Through this agreement, we will expand access to pharmaceutical starches and other functional excipients in the United States and Canada, helping our pharmaceutical and nutraceutical customers address formulation challenges and grow their businesses. This partnership truly underscores our commitment connecting customers to high-quality ingredients and customized market solutions, and we are optimistic that the collaboration will help enhance tableting, softgel, and encapsulation applications."

Ingredion Pharma Solutions, part of Ingredion, a global ingredient solutions provider, produces functional ingredients, including pharmaceutical-grade starches designed to enhance formulation performance and help overcome the technical challenges experienced in various pharmaceutical and nutraceutical applications. Through the agreement, Ingredients + Specialties from Univar Solutions will distribute Ingredion's pharma portfolio and is the exclusive distributor in the United States and Canada for the Pharma starch-based excipients including UNI-PURE^® F, UNI-PURE^® FL, UNI-PURE^® GA, and UNI-PURE^® WG-220.

"We are excited to expand our partnership with Ingredients + Specialties from Univar Solutions in the pharmaceutical starches, mannitol, and specialty excipients product space," said Joe Rogus, pharma senior sales manager – United States and Canada for Ingredion. "They are a world-class organization with an excellent track record in delivering high-value specialty products and services to pharmaceutical markets. We're confident that this collaboration will drive ingredient innovation and deliver exceptional value to our customers."

The Ingredients + Specialties portfolio from Univar Solutions—one of the most trusted names in innovation and distribution—offers the essential specialty ingredients needed for brands and manufacturers to develop new and improved products that deliver results for their customers. The portfolio is backed by their commitment to innovation, sustainability, and quality, as well as technical support and formulation expertise to help ensure customers and suppliers are equipped to navigate the industry's rapidly changing future with confidence and creativity.

Explore how the relationship between Ingredients + Specialties from Univar Solutions and Ingredion Pharma Solutions enhances formulation performance and addresses technical challenges.

About Univar Solutions
Univar Solutions is a leading global specialty chemical and ingredient distributor representing a premier portfolio from the world's leading producers. With the industry's largest private transportation fleet and technical sales force, unparalleled logistics know-how, deep market and regulatory knowledge, formulation and recipe development, and leading digital tools, the Company is well-positioned to offer tailored solutions and value-added services to a wide range of markets, industries, and applications. While fulfilling its purpose to help keep communities healthy, fed, clean, and safe, Univar Solutions is committed to helping customers and suppliers innovate and focus on Growing Together. Learn more at univarsolutions.com.

About Ingredients + Specialties from Univar Solutions 
Ingredients + Specialties from Univar Solutions brings the best products, people, and results to specialty customers and suppliers seeking to power modern life. By combining science, innovation, and deep expertise with a leading specialty portfolio, we help find the solutions needed to safely improve lives and communities across the globe. Learn more at univarsolutions.com.

About Ingredion Pharma Solutions
Ingredion Incorporated (NYSE: INGR) is a global innovative ingredient solutions provider. For Pharma & Nutraceuticals, we partner with customers seeking functional materials to enhance the performance of formulations and overcome their technical challenges. Our solutions include binders, fillers, superdisintegrants, lubricants, plasticizer, gelatine replacers for veggie softgel, emulsions for encapsulation, and parenteral APIs. We are in the continuous transformation to combine cGMP facilities, regulatory assistance, global presence, and technical support to be a trusted formulation problem-solving partner to our customers. To learn more, access ingredionpharma.com/

Forward-Looking Statements and Information
This communication contains "forward-looking statements" under applicable law regarding financial and operating items relating to the Company's business. Forward-looking statements generally can be identified by words such as "believes," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates," "anticipates" or other comparable terms. All forward-looking statements made in this communication are qualified by this cautionary language.

Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond the Company's control, that could result in expectations not being realized or could otherwise materially and adversely affect the Company's business, financial condition, results of operations or cash flows. Although the forward-looking statements are based on what management believes to be reasonable assumptions, we caution you that the forward-looking information presented in this communication is not a guarantee of future events or results, and that actual events or results may differ materially from those made in or suggested by the forward-looking information contained in this communication. For additional information regarding factors that could affect the Company, please see the Company's most recent annual report and other financial reports, including the information set forth under the caption "Risk Factors." Any forward-looking statements represent the Company's views only as of the date of this communication and should not be relied upon as representing the Company's views as of any subsequent date, and the Company undertakes no obligation, other than as may be required by law, to update any forward-looking statement.

View original content to download multimedia:https://www.prnewswire.com/news-releases/univar-solutions-selected-as-ingredion-pharma-solutions-distributor-in-united-states-and-canada-302696052.html

SOURCE Univar Solutions LLC

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Univar Solutions announce about its distribution deal with Ingredion (INGR) on February 24, 2026?

Univar Solutions said it will distribute Ingredion's pharma portfolio and be the exclusive U.S. and Canada distributor for pharma starches. According to Ingredion and Univar Solutions, the agreement covers UNI-PURE branded starches, mannitol and other specialty excipients to support pharmaceutical formulation needs.

Which Ingredion products will Ingredients + Specialties from Univar Solutions distribute in the U.S. and Canada (INGR)?

The agreement includes Ingredion's pharma starches such as UNI-PURE F, UNI-PURE FL, UNI-PURE GA and UNI-PURE WG-220. According to Ingredion, distribution also covers mannitol and specialty excipients for tableting, softgel and encapsulation applications.

How does the Univar–Ingredion (INGR) partnership affect pharmaceutical customers in North America?

The partnership expands access to functional excipients and technical support for formulators in the U.S. and Canada. According to Univar Solutions, customers will gain broader availability of pharmaceutical starches and formulation expertise for direct compression, wet granulation and encapsulation challenges.

Is Univar Solutions the exclusive distributor for Ingredion pharma starches in the U.S. and Canada (INGR)?

Yes, Univar Solutions is appointed the exclusive distributor for Ingredion pharma starch-based excipients in the United States and Canada. According to the companies, exclusivity applies to specific UNI-PURE branded starches listed in the agreement.

Will the Ingredion (INGR) distribution deal change Univar Solutions' product offerings for nutraceutical manufacturers?

The agreement broadens Univar's nutraceutical and pharmaceutical ingredient portfolio with additional functional excipients and mannitol. According to Univar Solutions, this expands formulation options for nutraceutical customers addressing tablet, capsule and softgel applications.

Where can manufacturers expect application support after the Ingredion–Univar Solutions (INGR) agreement?

Manufacturers can expect technical formulation support and customized market solutions through Univar's Ingredients + Specialties team. According to Univar Solutions, the partnership pairs Ingredion's pharma-grade excipients with Univar's distribution and formulation expertise to address technical challenges.